AstraZeneca happy with Mondher Mahjoubi's 'equally brilliant' replacement

21 December 2016
jamie-freedman-az-large

News that AstraZeneca (LSE: AZN) was losing the experienced head of one its focus areas caused a slight share price wobble on Monday – but the company is confident that his shoes will be ably filled.

The Anglo-Swedish pharma major is losing Mondher Mahjoubi, its head of oncology, at the end of the month as he becomes chief executive of promising French biotech Innate Pharma (Euronext Paris: IPH), which is actually a partner of AstraZeneca in immuno-oncology.

A major reason for Dr Mahjoubi’s move is that it will enable him to be closer to his family in France, AstraZeneca has underlined. In a statement sent via email, the company also showed confidence in his replacement.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical